Recombinant Human VEGFR2/KDR His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10964-KD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10964-KD-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

AAC16450.1

Conjugate

Unconjugated

Applications

Bioactivity

View all VEGFR2/KDR/Flk-1 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human VEGFR2/KDR/Flk-1 protein
Ala20-Glu764, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala20

Predicted Molecular Mass

84 kDa

SDS-PAGE

114-126 kDa

Activity

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323.
The ED50 for this effect is 0.350-3.50 μg/mL.

Scientific Data Images for Recombinant Human VEGFR2/KDR His-tag Protein, CF

Recombinant Human VEGFR2/KDR/Flk-1 His-tag Protein Bioactivity.

Recombinant Human VEGFR2/KDR/Flk-1 His-tag Protein (Catalog # 10964-KD) inhibits the Recombinant Human VEGF165 (293-VE) dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 0.350-3.50 μg/mL.

Recombinant Human VEGFR2/KDR His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Human VEGFR2/KDR His-tag Protein (Catalog # 10964-KD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 114-126 kDa.

Formulation, Preparation and Storage

10964-KD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 1.00 mg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

Vascular endothelial Growth Factor Receptor 2 (VEGFR2), also known as FLK-1, KDR, and CD309, is a type I single-pass membrane receptor. Mature VEGFR2 contains a 745 amino acid extracelluar domain with seven immunoglobulin-like repeats, 21 transmembrane domain and 571 cytoplasmic domain. Within the extracellular domain, human VEGFR2 shares 80% homology with that of mouse and rat. VEGFR2, VEGFR1(Flt-1) and VEGFR3(Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors have almost exclusive expression in the endothelial cells and play essential roles in vasculogenesis and angiogenesis. VEGFR2 is the receptor for VEGF-A, VEGF-C, VEGF-D, and VEGF-E (viral homologs) (1, 2). Monomeric VEGFR2 dimerizes after binding to dimeric ligand and phosphorylate the Tyr in the cytoplasmic domain (3). VEGFR2 can also form heterodimer with VEGFR1 and VEGFR3 (4-6). Alternative splicing isoforms 2 and 3 which lack the transmembrane and cytoplasmic domains function as decoy receptors (7, 8). Targeting the signaling pathways of VEGFR1 and VEGFR2 are potential therapeutic targets for the treatment of inflammation and multiple tumors including breast, gastric, and lung carcinomas (9-12). Cancer immunotherapies using VEGF and VEGFR2 monoclonal antibodies may also be effective in combination with programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (13). 

References

  1. Ferra, N. and Davis-Smyth, T. (1997) Endocr. Rev. 18:4.
  2. Wise, L.M. et al. (2012) Cell Microbiol. 13:1376.
  3. Lepanen, V.M. et al. (2010) Proc. Natl. Acad. Sci. USA 107:2425.
  4. Cai, M. et al. (2017) Vascul. Pharmacol. 88:11.
  5. Nilsson, I. et al. (2010) EMBO J. 29:1377.
  6. Dixelius, J. et al. (2003) J. Biol. Chem. 278:40973.
  7. Albuquerque, R.J. et al. (2009) Nat. Med. 15:1023.
  8. Jin, P. et al. (2008) Arthritis Res. Ther. 10:R73.
  9. Shibuya, M. (2015) Endocr Metab Immune Disord Drug Targets. 15:135.
  10. Farzaneh Behelgardi, M. et al. (2020), Mol Biol Rep. 47:2061.
  11. Lian, L. et al. (2019) BMC Cancer. 19:183.
  12. Hu, C. et al. (2019) Onco. Targets Ther. 12:933.
  13. Gao, F. et al. (2020) Curr. Cancer Drug Targets. 20:3.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Alternate Names

CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Gene Symbol

KDR

UniProt

AAC16450.1

Additional VEGFR2/KDR/Flk-1 Products

Product Documents for Recombinant Human VEGFR2/KDR His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human VEGFR2/KDR His-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.